

GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS B INFECTION

MARCH 2015

GUIDELINES

GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS B INFECTION

MARCH 2015

WHO Library Cataloguing-in-Publication Data

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection.

1.Hepatitis B – prevention and control. 2.Hepatitis B – diagnosis. 3.Hepatitis B – drug therapy.
4.Guideline. I.World Health Organization.

ISBN 978 92 4 154905 9

(NLM classification: WC 536)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France.

Design and layout: blossoming.it

CONTENTS

ACKNOWLEDGEMENTS	IX
ABBREVIATIONS AND ACRONYMS	XII
GLOSSARY OF TERMS	XV
EXECUTIVE SUMMARY	XIX
Summary of recommendations for persons with chronic hepatitis B infection	xxii
Algorithm of WHO recommendations on the management of persons with chronic hepatitis B infection	xxvi
Structure of the guidelines along the continuum of care	xxviii
1. INTRODUCTION	1
1.1. Goals and objectives	1
1.2. Related WHO materials and guidelines	2
1.3. Target audience	2
1.4. Guiding principles	2
2. METHODOLOGY AND PROCESS OF DEVELOPING THE GUIDELINES	5
2.1. WHO guideline development process	5
2.2. Roles	8
2.3. Management of conflicts of interest	8
2.4. Disseminating and monitoring implementation of the guidelines	9
3. BACKGROUND	10
3.1. Epidemiology and burden	10
3.2. Virology	13
3.3. Transmission	13
3.4. Natural history of chronic hepatitis B	14
3.5. Diagnosis and staging	17
3.6. Screening	19
3.7. Prevention through vaccination	19
3.8. Antiviral therapy	20
3.9. Special populations	22

4. RECOMMENDATIONS: NON-INVASIVE ASSESSMENT OF LIVER DISEASE STAGE AT BASELINE AND DURING FOLLOW UP	25
4.1. Background	25
4.2. Summary of the evidence	28
4.3. Rationale for the recommendations	32
5. RECOMMENDATIONS: WHO TO TREAT AND WHO NOT TO TREAT IN PERSONS WITH CHRONIC HEPATITIS B	36
5.1. Background	39
5.2. Summary of the evidence	39
5.3. Rationale for the recommendations	44
6. RECOMMENDATIONS: FIRST-LINE ANTIVIRAL THERAPIES FOR CHRONIC HEPATITIS B	47
6.1. Background	48
6.2. Summary of the evidence	48
6.3. Rationale for the recommendations	51
7. RECOMMENDATIONS: SECOND-LINE ANTIVIRAL THERAPIES FOR MANAGEMENT OF TREATMENT FAILURE	58
7.1. Background	58
7.2. Summary of the evidence	59
7.3. Rationale for the recommendations	60
8. RECOMMENDATIONS: WHEN TO STOP TREATMENT	64
8.1. Background	65
8.2. Summary of the evidence	65
8.3. Rationale for the recommendations	66
9. RECOMMENDATIONS: MONITORING	69
9.1. Monitoring for disease progression and treatment response in persons with CHB prior to, during and post-treatment	69
9.1.1. Background	70
9.1.2. Summary of the evidence	71
9.1.3. Rationale for the recommendations	72
9.2. Monitoring for tenofovir and entecavir toxicity	74
9.2.1. Background	77
9.2.2. Summary of the evidence	77
9.2.3. Rationale for the recommendations	79
9.3. Monitoring for hepatocellular carcinoma (HCC)	81
9.3.1. Background	81
9.3.2. Summary of the evidence	81
9.3.3. Rationale for the recommendations	84

10. RECOMMENDATIONS FROM EXISTING WHO GUIDANCE: PREVENTION	87
10.1. Infant and neonatal hepatitis B vaccination	87
10.2. Prevention of mother-to-child HBV transmission using antiviral therapy	89
10.3. Prevention of hepatitis B transmission and measures to reduce disease progression in persons with chronic hepatitis B	94
10.4. Prevention of hepatitis B and C transmission in health-care settings	95
10.5. Prevention of hepatitis B and C and sexual transmission in persons who inject drugs	96
11. MANAGEMENT CONSIDERATIONS FOR SPECIFIC POPULATIONS	98
11.1. Coinfections	98
11.1.1. HBV/HIV coinfection	98
11.1.2. HBV/HDV coinfection	102
11.1.3. HBV/HCV coinfection	103
11.1.4. HBV/Tuberculosis coinfection	103
11.2. Decompensated cirrhosis and advanced liver disease	104
11.3. Extrahepatic manifestations	105
11.4. Acute hepatitis B	105
11.5. Children and adolescents	105
11.6. Pregnant women	106
11.7. Persons who inject drugs	106
11.8. Dialysis and renal transplant patients	106
11.9. Health-care workers	107
11.10. Indigenous peoples	107
12. IMPLEMENTATION CONSIDERATIONS FOR NATIONAL PROGRAMMES	108
12.1. Introduction	108
12.2. Key principles	108
12.3. Key considerations to support country planning and decision-making	109
REFERENCES	114

WEB APPENDICES

All Appendices will be available through weblink

(<http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/>)

Appendix 1: PICO questions

Appendix 2: Systematic review (SR) reports and evidence summaries

Appendix 3: Summary of declared interests

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27523

